产品
编 号：F255625
分子式：C33H43Cl2N3O2
分子量：584.62
分子式：C33H43Cl2N3O2
分子量：584.62
产品类型
规格
价格
是否有货
结构图
CAS No: 2088939-99-3
产品详情
生物活性：
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC).
体内研究：
LYN-1604 (low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg; intragastric administration once a day for 14 days) inhibits the growth of xenograft TNBC by targeting ULK1-modulated cell death.Animal Model:24 female nude mice (BALB/c, 6-8 weeks, 20-22 g)
Dosage:Low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg
Administration:Intragastric administration; once a day for 14 days
Result:Significantly inhibited the growth of xenograft MDA-MB-231 cells. The body weights of mice were stable. By the end of the experiment, the liver and spleen weight indexes of mice were slightly increased in parts of the groups, while the kidney weight index was not affected in all dose groups.
体外研究：
LYN-1604 is a potential ULK1 agonist (enzymatic activity=195.7% at 100 nM and IC50=1.66 μM against MDA-MB-231 cells) . LYN-1604 binds to wild-type ULK1 with a binding affinity in the nanomole range (KD=291.4 nM) .LYN-1604 (0.5, 1.0 and 2.0 μM) induces cell death via the ULK complex in MDA-MB-231 cells.LYN-1604 (0.5-2 μM, 24 hours) induces remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II in MDA-MB-231 cells.LYN-1604 induces ATG5-dependent autophagy via the ULK complex.LYN-1604 can also increase cleavage of caspase3 and induce apoptosis.
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC).
体内研究：
LYN-1604 (low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg; intragastric administration once a day for 14 days) inhibits the growth of xenograft TNBC by targeting ULK1-modulated cell death.Animal Model:24 female nude mice (BALB/c, 6-8 weeks, 20-22 g)
Dosage:Low dose, 25 mg/kg; median dose, 50 mg/kg; high dose, 100 mg/kg
Administration:Intragastric administration; once a day for 14 days
Result:Significantly inhibited the growth of xenograft MDA-MB-231 cells. The body weights of mice were stable. By the end of the experiment, the liver and spleen weight indexes of mice were slightly increased in parts of the groups, while the kidney weight index was not affected in all dose groups.
体外研究：
LYN-1604 is a potential ULK1 agonist (enzymatic activity=195.7% at 100 nM and IC50=1.66 μM against MDA-MB-231 cells) . LYN-1604 binds to wild-type ULK1 with a binding affinity in the nanomole range (KD=291.4 nM) .LYN-1604 (0.5, 1.0 and 2.0 μM) induces cell death via the ULK complex in MDA-MB-231 cells.LYN-1604 (0.5-2 μM, 24 hours) induces remarkable up-regulation of Beclin-1 and degradation of p62, as well as transformation of LC3-I to LC3-II in MDA-MB-231 cells.LYN-1604 induces ATG5-dependent autophagy via the ULK complex.LYN-1604 can also increase cleavage of caspase3 and induce apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备